title: [Endometrial cancer, estrogens and metabolic syndrome: scenario becomes more complicated].
abstract: Simultaneously with keeping one of the leading positions in the structure of oncogynecological morbidity, endometrial cancer (EC) presents for many decades 'the food for brains' of cancer endocrinologists. Step by step development of contemporary ideas and collecting the data on mechanisms of hormonal carcinogenesis, the role of excessive estrogenic stimulation and metabolic syndrome/insulin resistance as risk factors for EC, very probable gradual changing of the disease phenotype and significance of genetic damages (with PTEN-mutations as one of the examples), as a consequence point at potential perspectives in the usage of preventive and therapeutic approaches in this important area.
authors.forename: L M
authors.initials: LM
authors.lastname: Bershteĭn
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage / Q000009:adverse effects; D003278:Contraceptives, Oral, Hormonal / Q000008:administration & dosage; D048909:Diabetes Complications / Q000209:etiology / Q000517:prevention & control; D016889:Endometrial Neoplasms / Q000209:etiology* / Q000235:genetics / Q000517:prevention & control*; D004967:Estrogens / Q000009:adverse effects* / Q000378:metabolism; D005260:Female; D006801:Humans; D007333:Insulin Resistance; D024821:Metabolic Syndrome / Q000150:complications* / Q000378:metabolism; D009154:Mutation; D009765:Obesity / Q000150:complications; D051059:PTEN Phosphohydrolase / Q000235:genetics*; D010641:Phenotype; D012307:Risk Factors; D020845:Selective Estrogen Receptor Modulators / Q000008:administration & dosage / Q000009:adverse effects; D013629:Tamoxifen / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D018931:Antineoplastic Agents, Hormonal; D003278:Contraceptives, Oral, Hormonal; D004967:Estrogens; D020845:Selective Estrogen Receptor Modulators; D013629:Tamoxifen; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human